CN114028397A - Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis - Google Patents
Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis Download PDFInfo
- Publication number
- CN114028397A CN114028397A CN202110135717.7A CN202110135717A CN114028397A CN 114028397 A CN114028397 A CN 114028397A CN 202110135717 A CN202110135717 A CN 202110135717A CN 114028397 A CN114028397 A CN 114028397A
- Authority
- CN
- China
- Prior art keywords
- gsk126
- preventing
- treating
- ischemic stroke
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 title claims abstract description 82
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 206010008092 Cerebral artery thrombosis Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000000971 hippocampal effect Effects 0.000 claims abstract description 22
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 19
- 208000032382 Ischaemic stroke Diseases 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 208000006011 Stroke Diseases 0.000 claims description 22
- 210000002569 neuron Anatomy 0.000 claims description 13
- 230000034994 death Effects 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 tincture Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000011987 methylation Effects 0.000 abstract description 23
- 238000007069 methylation reaction Methods 0.000 abstract description 23
- 108010033040 Histones Proteins 0.000 abstract description 20
- 208000028867 ischemia Diseases 0.000 abstract description 16
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000016273 neuron death Effects 0.000 abstract description 4
- 239000002547 new drug Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 51
- 210000001320 hippocampus Anatomy 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 22
- 201000006474 Brain Ischemia Diseases 0.000 description 13
- 230000010410 reperfusion Effects 0.000 description 10
- 206010008120 Cerebral ischaemia Diseases 0.000 description 8
- 102000006947 Histones Human genes 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000010826 Nissl staining Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 210000004295 hippocampal neuron Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of GSK126 serving as an EZH2 inhibitor in preparation of a medicine for preventing and/or treating cerebral arterial thrombosis, and belongs to the field of biological medicines. According to the invention, the activity of EZH2 is inhibited by GSK126, so that the methylation level of rat hippocampal histone H3K27me3 can be reduced, the methylation level of hippocampal histone H3K27me3 can be prevented from being excessively increased after ischemic stroke occurs, and meanwhile, GSK126 is found to remarkably reduce neuron death of hippocampal CA1 area caused by ischemia and reduce the cerebral infarction area after ischemic stroke. Therefore, the GSK126 provided by the invention can be used for preventing and/or treating the ischemic stroke, provides a new drug choice for preventing and/or treating the ischemic stroke, and provides a new strategy and treatment mode for clinically treating the ischemic stroke.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to application of GSK126 serving as an EZH2 inhibitor in preparation of medicines for preventing and/or treating cerebral arterial thrombosis.
Background
Stroke is one of the three most fatal diseases in humans and is also the most common cause of disability. The latest statistical data show that: the proportion of people who may suffer stroke is up to one sixth. Stroke includes stroke and heart stroke, and stroke is also called stroke or cerebrovascular accident, and is an acute ischemic or hemorrhagic brain disease caused by circulatory disturbance of cerebral blood flow, so stroke is divided into ischemic stroke and hemorrhagic stroke.
At present, the treatment scheme for cerebral apoplexy is very limited, thrombolytic treatment medicines are generally used as main treatment means after the occurrence of the cerebral apoplexy, but the medicines capable of simultaneously preventing and treating the cerebral apoplexy are not reported. Moreover, the cause of direct neuronal damage, whether ischemic or hemorrhagic, is ischemic brain injury. After ischemia occurs, neuronal survival is determined by a balance of cell death and cytoprotective function that involves changes in the expression levels of hundreds of genes. H3K27me3 is a histone methylation form capable of widely inhibiting gene expression levels, while the H3K27me3 levels of the elderly are generally high. It is known that H3K27me3 levels are specifically mediated by the histone methylase EZH2 and affect the DNA methylation level at CG sites on adjacent DNA strands. EZH2 activity can be specifically inhibited by GSK126, and thereby reduce H3K27me3 levels. After the occurrence of stroke, the level of H3K27me3 in ischemic brain tissue is further increased, and whether the stroke can be prevented and treated by a mode that H3K27me3 level can be reversed by GSK-126 is unknown. Therefore, the deep research on the effect and the specific mechanism of the GSK-126 in the stroke is helpful for determining the activity level and the action mechanism of the EZH2 in the stroke, and provides a new strategy and thought for the treatment of the stroke.
Disclosure of Invention
The invention aims to provide a novel medical application of GSK126, discusses the activity level and action mechanism of EZH2 in cerebral apoplexy, and provides important data for further developing drugs for preventing and/or treating ischemic cerebral apoplexy.
In order to achieve the purpose, the invention adopts the following technical scheme:
provides the application of GSK126 serving as an EZH2 inhibitor in preparing medicines for preventing and/or treating cerebral arterial thrombosis.
The molecular formula of the GSK126 is C31H38N6O2The structural formula is as follows:
preferably, the medicament is used for reducing the death rate of hippocampal neuronal cells and reducing cerebral infarction area.
Preferably, the GSK126 is used in an amount of 200 mg/kg.
In another aspect, the present invention provides a pharmaceutical preparation for preventing and/or treating ischemic stroke, comprising (1) an effective amount of GSK126 as an active ingredient, and (2) optionally a pharmaceutically acceptable carrier.
Preferably, the pharmaceutical dosage form is capsule, tablet, powder, oral liquid, pill, tincture, syrup or injection.
Animal experiments show that the methylation level of H3K27me3 in the hippocampus of a rat is obviously increased after ischemic stroke, and a massive death phenomenon occurs in neurons in the CA1 region of the hippocampus, which indicates that the methylation level of H3K27me3 is related to hippocampus death. According to the invention, the activity of EZH2 is inhibited by GSK126, so that the methylation level of rat hippocampal histone H3K27me3 can be reduced, the methylation level of hippocampal histone H3K27me3 can be prevented from being excessively increased after ischemic stroke occurs, and meanwhile, the GSK126 is found to remarkably reduce the neuron death of hippocampal CA1 area caused by cerebral ischemia and reduce the cerebral infarction area after ischemic stroke. Therefore, the GSK126 provided by the invention can be used for preventing and/or treating the ischemic stroke, provides a new drug choice for preventing and/or treating the ischemic stroke, and provides a new strategy and treatment mode for clinically treating the ischemic stroke.
Drawings
FIG. 1 is a graph showing the results of Western blot analysis of hippocampal cells before and after ischemia in rats, respectively, before and after GSK126 treatment (I/R); GSK126 indicates GSK126 pretreatment, I/R indicates four artery ligation whole brain ischemia reperfusion; "-" indicates that the treatment was not performed, "+" indicates that the treatment was performed;
FIG. 2 is a statistical graph (I/R) of the methylation level of H3K27me3 before and after GSK126 treatment of hippocampal cells of the brain before and after rat ischemia; wherein, Control is a Control group rat brain hippocampus sample which is not operated and administered, GSK126 is a group rat brain hippocampus sample which is pretreated by GSK126, I/R is a four-artery ligation whole brain ischemia reperfusion group rat brain hippocampus sample, and GSK126+ I/R is a four-artery ligation whole brain ischemia reperfusion group rat brain hippocampus sample after GSK126 pretreatment; data are expressed as Mean ± SEM, # p <0.001, # p <0.01, # p < 0.05;
fig. 3 is a graph of niemann's staining before and after treatment of hippocampal neuronal cells with GSK126 before and after rat ischemia: (A) nissl staining of rat hippocampal neuronal cells without ischemia and treatment with GSK126 injection (Control group); (B) nissl staining pattern of rat hippocampal neuronal cells treated with GSK126 alone (GSK126 group); (C) nissl staining pattern of ischemia reperfusion treated rat hippocampal neuronal cells only (group I/R); (D) nissl staining patterns of rat hippocampal neuronal cells treated with both ischemia reperfusion and pre-injection of GSK126 (I/R + GSK126 group); the small picture in each group of pictures is the amplification effect of the hippocampal CA1 region, and the scale bar is 1: 200 of a carrier;
FIG. 4 is a statistical chart of the cell numbers of hippocampal neurons before and after rat ischemia treatment by GSK126, respectively; wherein, Control is a Control group rat brain hippocampus sample which is not operated and administered, GSK126 is a group rat brain hippocampus sample which is pretreated by GSK126, I/R is a four-artery ligation whole brain ischemia reperfusion group rat brain hippocampus sample, and GSK126+ I/R is a four-artery ligation whole brain ischemia reperfusion group rat brain hippocampus sample after GSK126 pretreatment; data are expressed as Mean ± SEM, # p <0.01, # p <0.05, ns indicates no significant difference;
FIG. 5 is a graph showing the results of Western blot analysis of hippocampal cells before and after rat ischemia treatment with GSK126, respectively (MCAO); GSK126 represents GSK126 pretreatment, and MCAO represents rat cerebral artery embolism modeling; "-" indicates that the treatment was not performed, "+" indicates that the treatment was performed;
FIG. 6 is a statistical chart of the methylation level of H3K27me3 (MCAO) before and after GSK126 treatment of hippocampal cells of the brain before and after rat ischemia; wherein, Control is a Control rat brain hippocampus sample without operation and administration, GSK126 is a rat brain hippocampus sample pretreated by GSK126, MCAO is a rat brain hippocampus sample of a rat brain middle artery embolism modeling group, and GSK126 and MCAO are rat brain hippocampus samples of the rat brain middle artery embolism modeling group pretreated by the GSK 126; data are expressed as Mean ± SEM, # p <0.001, # p <0.01, # p < 0.05.
Fig. 7 is a TTC staining pattern of rats modeled by MCAO before and after treatment with GSK126, respectively: TTC staining pattern (Control group) after modeling of cerebral MCAO of rats not injected with GSK 126; TTC staining pattern after brain MCAO modeling of rats injected with GSK126 (GSK126 group); wherein the white areas show areas of cerebral infarction;
FIG. 8 is a statistical graph of infarct size of rats modeled by MCAO before and after treatment with GSK126, wherein Control is a group modeled by MCAO without GSK126 pretreatment, and GSK126 is a group modeled by MCAO and preprocessed by GSK 126; data are expressed as Mean ± SEM,. xp < 0.05.
Detailed Description
The invention is described in further detail below with reference to the figures and specific examples.
Unless otherwise indicated, reagents, methods and equipment used in the present invention are conventional in the art, and materials of kits used in the following examples are commercially available.
Example 1
Provides the application of GSK126 serving as an EZH2 inhibitor in preparing medicines for preventing and/or treating cerebral arterial thrombosis. The medicine is used for reducing the death rate of hippocampal neuron cells and reducing cerebral infarction area.
The specific experimental process is as follows:
experimental animals: male SD rats were purchased from the laboratory animal center of Xuzhou medical university under license number SCXK (Su) 2015-. Rats are placed under the standard conditions of humidity of 50 +/-10% and temperature of 23 +/-2 ℃ for adapting to survival for 12 hours in each day and night. Rats can drink and eat freely. All animal management and treatment protocols were approved by the animal ethics committee of xu nationality medical university. All experiments were performed as recommended by the ethical guidelines for managing and using animal behavior.
Reagent: GSK126 was purchased from bioengineering, inc.
Antibody: H3K27me3 and Histone H3 were both available from Abcam, USA.
First, GSK126 reduces ischemia-induced neuronal death in CA1 region of hippocampus cerebri by reducing histone H3K27me3 methylation level and inhibiting H3K27me3 elevation
(1) Establishment and administration of rat four-artery ligation cerebral ischemia reperfusion model (I/R)
Rats were first administered a 200mg/kg/day dose of GSK126 by lateral ventricle injection for seven consecutive days. Electrocoagulation of vertebral arteries on two sides of the rat on the seventh day, surgical ligation of carotid artery for 15min on the eighth day to cause cerebral ischemia model, releasing carotid artery after 15min for blood reperfusion, and taking brain tissue of the rat according to the time required by the study to carry out the next study.
(2) Detection of histone H3K27me3 methylation level by Western blotting method
Histone H3K27me3 methylation level assay material was taken from rat brain hippocampus CA1 region tissue 24H after I/R model surgery, hippocampus tissue was immediately lysed with RIPA lysate, protein was separated by 10% SDS-PAGE gel electrophoresis after centrifugation to remove precipitates, protein isolate was transferred to Nitrocellulose (NC) membrane, and 3% BSA blocked for 1H. And (3) incubating the NC membrane with the corresponding primary antibody at 4 ℃ overnight, eluting the next day, adding the corresponding secondary antibody, and incubating for 1h at room temperature. Antibodies used included H3K27me3, Histone H3. And (4) ECL developing, scanning by a fluorescence imaging system to form a graph, and expressing the relative expression content of the target protein by the ratio of optical density.
(3) Neisser's staining method for detecting survival condition of rat hippocampal neuron
Tissues for observation of neural cell survival were obtained from rat brain tissue 7 days after surgery. Taking out brain, slicing with paraffin, dewaxing to water, and dewatering with gradient alcohol. Repeatedly washing with distilled water, placing in a warm box, and dyeing with tar violet for 30 s. Eluting with distilled water, dehydrating in ethanol, treating with xylene, and sealing with neutral gum.
(4) Results of the experiment
The results of western blot experiments are shown in fig. 1 and fig. 2, with Histone H3 as an internal reference, and the ratio of H3K27me3 to Histone H3 as a reference value of the methylation level of H3K27me3, it was found that GSK126 pretreatment can effectively reduce the level of rat hippocampus H3K27me3 (Control vs. GSK 126: 0.6035 ± 0.0088vs.0.3244 ± 0.0788, p <0.05), and that the methylation level of H3K27me3 caused by global cerebral ischemia can be effectively inhibited (Control vs. I/R: 0.6035 ± 0.0088vs.1.505 ± 0.0874, p <0.001) (I/R vs. GSK126+ I/R: 1.505 ± 0.0874vs.0.5697 ± 0.1104, p <0.01), and the difference has statistical significance (p < 0.05). The results suggest that GSK126 pretreatment can effectively inhibit the elevated level of methylation of H3K27me3 in brain tissue after global cerebral ischemia.
The results of the Neisseria staining are shown in FIGS. 3 and 4, and FIG. 3 shows the normal survival of neurons in purple. Based on the number of neurons in CA1 area of hippocampal in Control (Control) rats, the pretreatment of GSK126 did not affect the survival number of neurons in CA1 area of hippocampus (FIG. 4, Control vs. GSK126: 84 + -8.021 vs.82 + -5.200), and the neurons in CA1 area of hippocampus of rats suffered from massive death after global cerebral ischemia (FIG. 4, Control vs. I/R:84 + -8.021 vs.37 + -5.196, p <0.01), and the pretreatment of GSK126 could effectively save the death of hippocampal neurons after global cerebral ischemia (FIG. 4, I/R vs. GSK126+ I/R: 37 + -5.196 vs.68.67 + -6.888, p < 0.05). The results suggest that GSK126 pretreatment can effectively rescue hippocampal CA1 area neurons from dying after stroke.
II, GSK126 reduces cerebral infarction area after ischemia by reducing histone H3K27me3 methylation level and inhibiting H3K27me3 from rising
(1) Establishment and administration of Middle artery occlusion model (Middle artery occlusion/reperfusion, MCAO) in rat
Rats were first given a 200mg/kg/day dose of GSK126 by lateral ventricle injection for seven consecutive days. The common carotid artery, the external carotid artery and the internal carotid artery are separated bluntly after the rat is anesthetized. The common carotid artery and the external carotid artery are ligated, the internal carotid artery is clamped by an artery clamp, and a small opening is cut at the common carotid artery to insert a prepared fish line.
(2) Detection of histone H3K27me3 methylation level by Western blotting method
Histone H3K27me3 methylation level detection material rat brain hippocampus CA1 region tissue 24H after MCAO model operation is taken, hippocampus tissue is immediately cracked by RIPA lysate, protein is separated by 10% SDS-PAGE gel electrophoresis after sediment is removed by centrifugation, the separated protein is transferred to a Nitrocellulose (NC) membrane, and 3% BSA is blocked for 1H. And (3) incubating the NC membrane with the corresponding primary antibody at 4 ℃ overnight, eluting the next day, adding the corresponding secondary antibody, and incubating for 1h at room temperature. Antibodies used included H3K27me3, Histone H3. And (4) ECL developing, scanning by a fluorescence imaging system to form a graph, and expressing the relative expression content of the target protein by the ratio of optical density.
(3) Detection of cerebral infarction area of rat by TTC staining method
Taking brain, quickly freezing in refrigerator at-20 deg.C for 20min, and slicing. And placing the slices in TTC, covering with tin foil paper, and placing in a 37 ℃ incubator for 15-30 min. Effect after dyeing: white is subcortical infarction.
(4) Results of the experiment
As shown in fig. 5 and fig. 6, with Histone H3 as an internal reference, and the ratio of H3K27me3 to Histone H3 as a reference value of the methylation level of H3K27me3, it was found that GSK126 pretreatment can effectively reduce the level of H3K27me3 in rat hippocampus (Control vs. GSK 126: 1.109 ± 0.096vs.0.7935 ± 0.0309, p <0.05), and that ischemia-induced cerebral ischemia (MCAO) can effectively inhibit the methylation level of H3K27me3 in ischemia-reperfusion region (Control vs. MCAO: 1.109 ± 0.096vs.2.026 ± 0.1553, p <0.01) (MCAO vs. GSK126+ MCAO: 2.026 ± 0.1553vs. 1.1. ± 0.0882, p < 0.456), and that the difference is less than 0.05 (p < 0.05). The results suggest that GSK126 pretreatment can effectively inhibit the increase of the methylation level of H3K27me3 in the ischemic brain tissue after the ischemic brain.
TTC staining results are shown in fig. 7 and 8, and white areas shown in fig. 7 are infarcted brain tissues, and each group of infarcted middle cerebral artery (right side) showed a cerebral tissue infarct compared to non-infarcted middle cerebral artery (left side) brain tissues, but it can be seen from fig. 8 that GSK126 pretreatment was effective in reducing the cerebral infarct area caused by MCAO (control vs. GSK 126: 0.73 ± 0.013vs.0.46 ± 0.074, p < 0.05).
The animal experiments show that the GSK126 can inhibit the activity of EZH2, so that the methylation level of rat hippocampal histone H3K27me3 can be reduced, the methylation level of hippocampal histone H3K27me3 can be prevented from being excessively increased after ischemic stroke occurs, and meanwhile, the GSK126 can obviously relieve the neuron death of a hippocampal CA1 area caused by ischemia and reduce the cerebral infarction area after ischemic stroke. Shows that GSK126 can be used as an EZH2 inhibitor in the preparation of medicines for preventing and/or treating cerebral arterial thrombosis.
Claims (5)
- Application of GSK126 serving as an EZH2 inhibitor in preparation of medicines for preventing and/or treating cerebral arterial thrombosis.
- 2. Use of GSK126 as EZH2 inhibitor for the preparation of a medicament for the prevention and/or treatment of stroke, according to claim 1, for reducing the death rate of hippocampal neuronal cells and reducing the cerebral infarct size.
- 3. The use of GSK126 as an EZH2 inhibitor for the preparation of a medicament for the prevention and/or treatment of stroke, as claimed in claim 1, wherein GSK126 is used in an amount of 200 mg/kg.
- 4. A pharmaceutical preparation for preventing and/or treating ischemic stroke, comprising (1) an effective amount of GSK126 as an active ingredient, and (2) optionally a pharmaceutically acceptable carrier.
- 5. The pharmaceutical preparation for preventing and/or treating ischemic stroke according to claim 3, wherein the pharmaceutical dosage form is capsule, tablet, powder, oral liquid, pill, tincture, syrup or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110135717.7A CN114028397A (en) | 2021-02-01 | 2021-02-01 | Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110135717.7A CN114028397A (en) | 2021-02-01 | 2021-02-01 | Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028397A true CN114028397A (en) | 2022-02-11 |
Family
ID=80139571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110135717.7A Pending CN114028397A (en) | 2021-02-01 | 2021-02-01 | Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028397A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
| CN107105651A (en) * | 2014-11-06 | 2017-08-29 | 达纳-法伯癌症研究所股份有限公司 | Ezh2 inhibitor and application thereof |
-
2021
- 2021-02-01 CN CN202110135717.7A patent/CN114028397A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
| CN107105651A (en) * | 2014-11-06 | 2017-08-29 | 达纳-法伯癌症研究所股份有限公司 | Ezh2 inhibitor and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| HANG XUE等: "Sevoflurane post-conditioning alleviates neonatal rat hypoxic-ischemic cerebral injury via Ezh2-regulated autophagy", 《DRUG DESIGN, DEVELOPMENT AND THERAPY》 * |
| JIAN CHEN等: "EZH2 inhibitor DZNep modulates microglial activation and protects against ischaemic brain injury after experimental stroke", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Galangin ameliorates cardiac remodeling via the MEK1/2–ERK1/2 and PI3K–AKT pathways | |
| Chang et al. | Indigo naturalis and its component tryptanthrin exert anti-angiogenic effect by arresting cell cycle and inhibiting Akt and FAK signaling in human vascular endothelial cells | |
| Deraniyagala et al. | Antinociceptive effect and toxicological study of the aqueous bark extract of Barringtonia racemosa on rats | |
| CN114306296A (en) | Application of disulfiram in preparation of medicine for treating membranous nephropathy | |
| Awadzi et al. | The chemotherapy of Onchocerciasis VIII: levamisole and its combination with the benzimidazoles | |
| CN102836145B (en) | Applications of pterostilbene in preparation of medicines for preventing and treating chronic glomerular disease | |
| CN109381473A (en) | Scutelloside is in the application for preparing gestational diabetes Fetal neurotubules malformation drug | |
| Wu et al. | Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice | |
| CN114028397A (en) | Application of GSK126 serving as EZH2 inhibitor in preparation of medicine for preventing and/or treating cerebral arterial thrombosis | |
| US20060269568A1 (en) | Reduction of embryonic neural tube defects by pre-or early-administration of germination-activated sporoderm-broken ganoderma lucidum spores to pregnant female | |
| Li et al. | Xiangshao Granules reduce the aggressive behavior and hippocampal injury of premenstrual irritability in rats by regulating JIK/JNK/p38 signal pathway | |
| CN110801456A (en) | Application of cordycepin in preparation of liver protection product | |
| CN110179773A (en) | Dendrophnol prevents and treats the application in Chronic glomerular disease drug in preparation | |
| CN108888623A (en) | Application of tyrosine protein kinase JAK2 inhibitor BX795 | |
| CN106038533B (en) | Application of the 5 hydroxymethyl furfural in anti-ovarian-senescedrug drug is prepared | |
| Tang et al. | Upregulation of PGC-1α expression by pioglitazone mediates prevention of sepsis-induced acute lung injury | |
| CN112843065B (en) | Medicine for cognitive disorder and preparation method thereof | |
| KR20040087352A (en) | Pharmaceutical composition for treating Alzheimer disease comprising as main ingredients Panax ginseng, Gastrodia elata, Biotae semen, Schizandra chinensis, Evodia rutaecarpa, Zizyphi spinosi semen pharmaceutical preparations containing them | |
| CN110384705B (en) | Application of crataegolic acid in preparation of medicine for treating type2diabetes islet cell injury | |
| CN113768943B (en) | Use of TLR4 pathway inhibitors in the manufacture of a medicament | |
| CN117085006B (en) | Application of salvianolic acid Y in preparing medicament for treating urticaria | |
| RU2776131C1 (en) | Method for treatment of polycystic ovarian syndrome based on experimental model of wistar rats | |
| CN114767866B (en) | Application of NURR1 gene as target in preparation of non-alcoholic fatty liver disease treatment drug | |
| CN106619602A (en) | Novel application of leonurine | |
| KR101111522B1 (en) | Composition for the treatment and/or prevention of neurological ischemic brain disease by using Laurus nobilis leaves extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220211 |